| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1053504363 |
| P356 | DOI | 10.1007/S00441-013-1637-3 |
| P698 | PubMed publication ID | 23712457 |
| P50 | author | Leopold Schmetterer | Q42104184 |
| Ernst R Tamm | Q54198073 | ||
| P2093 | author name string | Franz Grehn | |
| P2860 | cites work | Longitudinal Study of Cone Photoreceptors during Retinal Degeneration and in Response to Ciliary Neurotrophic Factor Treatment | Q24611007 |
| Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells | Q28567866 | ||
| Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. | Q30497967 | ||
| Early microglia activation in a mouse model of chronic glaucoma | Q30587345 | ||
| Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration | Q30832375 | ||
| Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial | Q30881058 | ||
| Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey | Q30990645 | ||
| Glaucoma and optic nerve repair. | Q38091321 | ||
| Imaging of retinal ganglion cells in glaucoma: pitfalls and challenges | Q38091322 | ||
| Electrophysiology and glaucoma: current status and future challenges | Q38092701 | ||
| Development of diagnostic and treatment strategies for glaucoma through understanding and modification of scleral and lamina cribrosa connective tissue | Q38093773 | ||
| The potential of stem cell research for the treatment of neuronal damage in glaucoma. | Q38109499 | ||
| The role of Müller glia and microglia in glaucoma | Q38115460 | ||
| Imaging apoptosis in the eye. | Q38375518 | ||
| Norrin mediates neuroprotective effects on retinal ganglion cells via activation of the Wnt/beta-catenin signaling pathway and the induction of neuroprotective growth factors in Muller cells. | Q39709676 | ||
| Clinical evidence for neuroprotection in glaucoma. | Q42591108 | ||
| The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. | Q42677806 | ||
| Comparison of different spectral domain optical coherence tomography scanning areas for glaucoma diagnosis | Q43056754 | ||
| Neuroprotective and axon growth-promoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor | Q43244105 | ||
| Disease modification in Parkinson's disease | Q44713421 | ||
| Excitotoxic death of retinal neurons in vivo occurs via a non-cell-autonomous mechanism. | Q46031528 | ||
| Retinal nerve fiber layer birefringence evaluated with polarization sensitive spectral domain OCT and scanning laser polarimetry: a comparison. | Q46062936 | ||
| The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium | Q46250580 | ||
| Analysis of autoantibodies against human retinal antigens in sera of patients with glaucoma and ocular hypertension | Q46694030 | ||
| Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma | Q46704887 | ||
| The Heidelberg retina tomograph Glaucoma Probability Score: reproducibility and measurement of progression. | Q51760440 | ||
| The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. | Q53872479 | ||
| Primary open-angle glaucoma | Q57728691 | ||
| A new statistical approach for quantifying change in series of retinal and optic nerve head topography images | Q31162778 | ||
| High-resolution imaging with adaptive optics in patients with inherited retinal degeneration | Q33288807 | ||
| Sera of glaucoma patients show autoantibodies against myelin basic protein and complex autoantibody profiles against human optic nerve antigens | Q33314556 | ||
| Effect of CNTF on retinal ganglion cell survival in experimental glaucoma | Q33390314 | ||
| Bidirectional Doppler Fourier-domain optical coherence tomography for measurement of absolute flow velocities in human retinal vessels | Q33392639 | ||
| High-resolution ocular imaging: combining advanced optics and microtechnology | Q33505740 | ||
| Agreement for detecting glaucoma progression with the GDx guided progression analysis, automated perimetry, and optic disc photography | Q33520857 | ||
| Retinal Ganglion Cell Loss in a Rat Ocular Hypertension Model Is Sectorial and Involves Early Optic Nerve Axon Loss | Q33681832 | ||
| Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement | Q34255732 | ||
| Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants | Q34410761 | ||
| The definition and classification of glaucoma in prevalence surveys | Q34508710 | ||
| Glaucomatous cupping of the lamina cribrosa: a review of the evidence for active progressive remodeling as a mechanism | Q34520898 | ||
| The potential of annexin-labelling for the diagnosis and follow-up of glaucoma | Q34570419 | ||
| Optical properties of retinal tissue and the potential of adaptive optics to visualize retinal ganglion cells in vivo | Q34636075 | ||
| Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions | Q34770260 | ||
| Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration | Q34794630 | ||
| Neuroprotection trials in Parkinson's disease: systematic review | Q34913056 | ||
| A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma | Q35082369 | ||
| Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review | Q35327935 | ||
| Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function | Q35520003 | ||
| The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity | Q35571666 | ||
| Improving the repeatability of Heidelberg retina tomograph and Heidelberg retina tomograph II rim area measurements. | Q35593963 | ||
| New considerations in the design of clinical trials for amyotrophic lateral sclerosis | Q35910744 | ||
| Immunoproteomic analysis of potential serum biomarker candidates in human glaucoma | Q36467223 | ||
| Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma | Q36639100 | ||
| State-of-the-art retinal optical coherence tomography | Q37013481 | ||
| Mechanical environment of the optic nerve head in glaucoma | Q37180776 | ||
| Neuroprotection in Parkinson's disease: myth or reality? | Q37203405 | ||
| Neurotrophic factor delivery as a protective treatment for glaucoma | Q37777778 | ||
| Neuroprotection in glaucoma – Is there a future role? | Q37783712 | ||
| Polarization sensitive optical coherence tomography in the human eye. | Q37897749 | ||
| Advances in glaucoma treatment and management: surgery | Q38007909 | ||
| Autocrine and paracrine interactions and neuroprotection in glaucoma | Q38077464 | ||
| Neurotrophic molecules in the treatment of neurodegenerative disease with focus on the retina: status and perspectives | Q38086746 | ||
| Challenges in the development of glaucoma neuroprotection therapy | Q38087849 | ||
| P433 | issue | 2 | |
| P921 | main subject | white paper | Q223729 |
| P304 | page(s) | 347-354 | |
| P577 | publication date | 2013-05-28 | |
| P1433 | published in | Cell and Tissue Research | Q1524113 |
| P1476 | title | Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper | |
| P478 | volume | 353 |
| Q26775083 | Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives |
| Q26765508 | The Endocannabinoid System as a Therapeutic Target in Glaucoma |
| Q48190647 | The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. |
Search more.